Hormone Replacement Therapy Companies

  • Report ID: 866
  • Published Date: Jun 25, 2025
  • Report Format: PDF, PPT

Key Hormone Replacement Therapy Market Players:

    The market is highly competitive, with leading players being Pfizer, Novo Nordisk, and Bayer. The lead the market by various strategies such as product innovation, regional expansion in the emerging countries, and strategic alliances. Companies in the Asia Pacific region prioritize accessibility and cost, while those in the US and Europe concentrate on lifecycle management and customized treatments. Many companies are increasingly integrating digital health platforms for remote monitoring and hormone replacement therapies.

    Here is a list of key players operating in the global market: 

    Company Name

    Country of Origin

    Industry Focus

    Estimated Market Share (%)

    Pfizer Inc.

    USA

    Offers branded HRT like Premarin and therapies for menopause and osteoporosis.

    13.8%

    AbbVie Inc.

    USA

    Produces Estradiol patches (Climara) and combination therapies.

    12.3%

    Novo Nordisk A/S

    Denmark

    Vagifem and systemic estrogen solutions; expanding into hormone-metabolic care.

    9.9%

    Bayer AG

    Germany

    Offers oral and transdermal estrogen-progestin combos under global brands.

    7.4%

    Merck KGaA

    Germany

    Focuses on endocrine health, women’s hormone research and delivery innovations.

    5.9%

    Teva Pharmaceutical Industries

    Israel

    Global supplier of generic HRT, including Estradiol patches and creams.

    xx%

    Mylan N.V. (Viatris Inc.)

    USA

    Broad generic HRT portfolio and growing APAC presence.

    xx%

    Theramex

    UK

    Women’s health specialist; strong HRT brands like Livial and FemSeven.

    xx%

    Besins Healthcare

    France

    Pioneers in transdermal HRT and testosterone gel solutions.

    xx%

    Gedeon Richter Plc.

    Hungary

    Focus on menopause and bioidentical hormones across Europe.

    xx%

    Shionogi & Co., Ltd.

    Japan

    Manufactures Estrana patches; growing East Asia market share.

    xx%

    Aska Pharmaceutical Co., Ltd.

    Japan

    Oral HRT product range; R&D-backed female hormone therapies.

    xx%

    Abbott Laboratories

    USA

    Combines hormone diagnostics and therapeutics; expanding diagnostics-HRT solutions.

    xx%

    Sun Pharmaceutical Industries

    India

    Produces low-cost estradiol and combination therapies in global markets.

    xx%

    Cipla Ltd.

    India

    Focuses on hormone tablets, transdermal gels; expanding in Africa & SEA.

    xx%

    Daewoong Pharmaceutical Co.

    South Korea

    Offers oral and patch-based HRT; innovation in local delivery tech.

    xx%

    Samsung Biologics

    South Korea

    CDMO partner in hormone biologics; rising biosimilar footprint.

    xx%

    Mayne Pharma Group Ltd.

    Australia

    Manufactures FDA-approved oral and transdermal estrogen products.

    xx%

    Duopharma Biotech Berhad

    Malaysia

    Leading Malaysian pharma offering HRT generics through public healthcare.

    xx%

    Organon & Co.

    USA

    Spun off from Merck; HRT brand portfolio includes Estalis and Marvelon.

    xx%

    Below are the areas covered for each company in the market:
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In 2025, the industry size of the hormone replacement therapy is assessed at USD 18.9 billion.

Hormone Replacement Therapy Market size was estimated at over USD 17.9 billion in 2024 and is projected to reach USD 33.5 billion by the end of 2037, exhibiting a CAGR of 5.8% during the forecast period 2025-2037.

The hormone replacement therapy market in North America is dominating and is poised to have a market share of 42.8% at the CAGR 6.1% by 2037.

Pfizer Inc., AbbVie Inc., Novo Nordisk A/S, Bayer AG, Merck KGaA, Teva Pharmaceutical Industries, Mylan N.V. (Viatris Inc.), Theramex, Besins Healthcare, Gedeon Richter Plc., Shionogi & Co., Ltd., Aska Pharmaceutical Co., Ltd., Abbott Laboratories, Sun Pharmaceutical Industries, Cipla Ltd., Daewoong Pharmaceutical Co., Samsung Biologics, Mayne Pharma Group Ltd., Duopharma Biotech Berhad, Organon & Co.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos